$Humanigen, Inc.(HGEN)$ NIH Ad

NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19

ACTIV-5/BET-B trial amended in the context of Humanigen’s positive Phase 3 lenzilumab LIVE-AIR study

Primary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/L

Study modification may enable Humanigen to use ACTIV-5/BET-B as a confirmatory study to support a future Biologics License Application (BLA)

Approximately half of the 400 patients are already enrolled in ACTIV-5/BET-B

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

ShaunDaSheep
2021-08-11
ShaunDaSheep
Nice

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":802987842,"tweetId":"802987842","gmtCreate":1627707366786,"gmtModify":1703495055383,"author":{"id":3574830102097482,"idStr":"3574830102097482","authorId":3574830102097482,"authorIdStr":"3574830102097482","name":"Klim8898","avatar":"https://static.tigerbbs.com/d68dfa512fc1b366a9d0046a0cca6701","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><a href=\"https://laohu8.com/S/HGEN\">$Humanigen, Inc.(HGEN)$</a>NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19ACTIV-5/BET-B trial amended in the context of Humanigen’s positive Phase 3 lenzilumab LIVE-AIR studyPrimary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/LStudy modification may enable Humanigen to use ACTIV-5/BET-B as a confirmatory study to support a future Biologics License Application (BLA)Approximately half of the 400 patients are already enrolled in ACTIV-5/BET-B</body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/HGEN\">$Humanigen, Inc.(HGEN)$</a>NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19ACTIV-5/BET-B trial amended in the context of Humanigen’s positive Phase 3 lenzilumab LIVE-AIR studyPrimary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/LStudy modification may enable Humanigen to use ACTIV-5/BET-B as a confirmatory study to support a future Biologics License Application (BLA)Approximately half of the 400 patients are already enrolled in ACTIV-5/BET-B</body></html>","text":"$Humanigen, Inc.(HGEN)$ NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19 ACTIV-5/BET-B trial amended in the context of Humanigen’s positive Phase 3 lenzilumab LIVE-AIR study Primary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/L Study modification may enable Humanigen to use ACTIV-5/BET-B as a confirmatory study to support a future Biologics License Application (BLA) Approximately half of the 400 patients are already enrolled in ACTIV-5/BET-B","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/802987842","repostId":0,"isVote":1,"tweetType":1,"viewCount":872,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["HGEN"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":535,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":5487811,"commentId":"5487811","gmtCreate":1628638081230,"gmtModify":1663232197334,"authorId":3575939427143002,"author":{"id":3575939427143002,"idStr":"3575939427143002","authorId":3575939427143002,"name":"ShaunDaSheep","avatar":"https://static.tigerbbs.com/0b4b20673ea5a6ab1d56dca8660ce608","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":802987842,"objectIdStr":"802987842","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Nice","text":"Nice","html":"Nice","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/802987842"}